The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

NCT01569438 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
107
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)